Valuation : Alligator Bioscience AB

Market Cap 18.84M 1.97M 1.69M 1.59M 1.45M 2.73M 188M 2.74M 7.35M 94.84M 7.38M 7.22M 314M P/E 2026 *
-
P/E 2027 * -
Enterprise Value 18.84M 1.97M 1.69M 1.59M 1.45M 2.73M 188M 2.74M 7.35M 94.84M 7.38M 7.22M 314M EV / Sales 2026 *
3.19x
EV / Sales 2027 * 0.38x
Free-Float
83.58%
Yield 2026 *
-
Yield 2027 * -
6 months-50.00%
Current year-99.55%
1 week 0
Extreme 0.0001
0.05
1 month 0
Extreme 0.0001
0.05
Current year 0
Extreme 0.0001
0.07
1 year 0
Extreme 0.0001
0.46
3 years 0
Extreme 0.0001
131.6
5 years 0
Extreme 0.0001
553
10 years 0
Extreme 0.0001
3,715
Manager TitleAgeSince
Chief Executive Officer 55 01/06/2021
Director of Finance/CFO 61 12/08/2024
Chief Tech/Sci/R&D Officer - 01/04/2025
Director TitleAgeSince
Chairman 55 -
Director/Board Member 64 01/06/2021
Director/Board Member 68 09/05/2022
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 1.97M
-0.78%-1.42%+2.96%+21.65% 50.47B
-6.00%-0.75%+447.48%+535.14% 44.56B
-0.24%+0.74%+37.18%+16.26% 43.08B
-1.55%-2.07%+19.83%+71.70% 41.7B
-0.31%-0.83%+19.47%+48.24% 33.21B
-1.79%-3.24%+26.32%+125.06% 16.77B
-0.58%-2.12% - - 16.28B
-0.88%-0.66%+11.63%+27.62% 14.58B
-1.66%-1.25%+78.49%+42.97% 13.92B
Average -1.38%-1.06%+80.42%+111.08% 30.51B
Weighted average by Cap. -1.70%-1.06%+96.28%+129.03%

Financials

2026 *2027 *
Net sales 5.9M 616K 530K 497K 454K 855K 58.83M 858K 2.3M 29.7M 2.31M 2.26M 98.47M 49.7M 5.18M 4.47M 4.19M 3.82M 7.2M 496M 7.23M 19.39M 250M 19.47M 19.04M 829M
Net income -15.2M -1.59M -1.37M -1.28M -1.17M -2.2M -152M -2.21M -5.93M -76.5M -5.95M -5.82M -254M 28.9M 3.01M 2.6M 2.44M 2.22M 4.19M 288M 4.2M 11.28M 145M 11.32M 11.07M 482M
Net Debt - -
Logo Alligator Bioscience AB
Alligator Bioscience AB is a Sweden-based biotechnology Company that develops antibody-based drugs for cancer treatment. The Company specializes in the development of tumor-targeted immunotherapies, in particular agonist mono- and bispecific antibodies, and is active in the early stages of drug development, from concept to phase II clinical trials. Alligator’s pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its technology platform, Neo-X-Prime, with MacroGenics Inc. and drug candidates based on the RUBY bispecific platform with Orion Corporation. Its licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. The Company operates domestically.
Employees
11
Date Price Change
28/08/26 €0.000100 0.00%
27/08/26 €0.000100 0.00%
26/08/26 €0.000100 0.00%
25/08/26 €0.000100 0.00%
24/08/26 €0.000100 0.00%
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B

Annual profits - Rate of surprise